Evidence map›Paper›PMID 32745568›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2020

Towards "CO in a pill": Pharmacokinetic studies of carbon monoxide prodrugs in mice.

Minjia Wang, Xiaoxiao Yang, Zhixiang Pan, Yingzhe Wang, Ladie Kimberly De La Cruz, Binghe Wang, Chalet Tan

Open access · greenAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 37 citations in OpenAlex.

  1. A Metal-Free Carbon Monoxide Prodrug Suppresses Metastasis of Pancreatic and Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Oral Delivery Systems for Gasotransmitters in Therapeutic Applications.Polymer science & technology (Washington, D.C.) · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. CO prodrugs: A new scaffold of adamantane-fused norbornen-7-ones with tunable water solubility.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024
    Article
  9. Review
  10. Review
  11. Click chemistry and drug delivery: A bird's-eye view.Acta pharmaceutica Sinica. B · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. "CO in a pill": Towards oral delivery of carbon monoxide for therapeutic applications.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Minjia WangDepartment of Pharmaceutics and Drug Delivery, University of Mississippi School of Pharmacy, University of Mississippi, MS 38677, USA.
Xiaoxiao YangDepartment of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303, USA.
Zhixiang PanDepartment of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303, USA.
Yingzhe WangDepartment of Pharmaceutics and Drug Delivery, University of Mississippi School of Pharmacy, University of Mississippi, MS 38677, USA.
Ladie Kimberly De La CruzDepartment of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303, USA.
Binghe WangDepartment of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303, USA. Electronic address: wang@gsu.edu.
Chalet TanDepartment of Pharmaceutics and Drug Delivery, University of Mississippi School of Pharmacy, University of Mississippi, MS 38677, USA. Electronic address: chalettan@olemiss.edu.
Georgia State University · USUniversity of Mississippi · US

Funding

Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis ModelsR01DK119202 · NIDDK · GEORGIA STATE UNIVERSITY · PI OTTERBEIN, LEO E, TAN, CHALET · 2019 to 2023
$3.6M
NIDDK NIH HHS R01 DK119202
6 · The paper itself

Abstract

Carbon monoxide (CO) is a known endogenous signaling molecule with potential therapeutic indications in treating inflammation, cancer, neuroprotection, and sickle cell disease among many others. One of the hurdles in using CO as a therapeutic agent is the development of pharmaceutically acceptable delivery forms for various indications. Along this line, we have developed organic CO prodrugs that allow for packing this gaseous molecule into a dosage form for the goal of "carbon monoxide in a pill." This should enable non-inhalation administration including oral and intravenous routes. These prodrugs have previously demonstrated efficacy in multiple animal models. To further understand the CO delivery efficiency of these prodrugs in relation to their efficacy, we undertook the first pharmacokinetic studies on these prodrugs. In doing so, we selected five representative prodrugs with different CO release kinetics and examined their pharmacokinetics after administration via oral, intraperitoneal, and intravenous routes. It was found that all three routes were able to elevate systemic CO level with delivery efficiency in the order of intravenous, oral, and intraperitoneal routes. CO prodrugs and their CO-released products were readily cleared from the circulation. CO prodrugs demonstrate promising pharmaceutical properties in terms of oral CO delivery and minimal drug accumulation in the body. This represents the very first study of the interplay among CO release kinetics, CO prodrug clearance, route of administration, and CO delivery efficiency.

Indexed as

ProdrugsAnimalsCarbon MonoxideKineticsMiceCarbon MonoxideProdrugsCarbon monoxide (CO)Carboxyhemoglobin (COHb)Controlled releaseFecal analysisOrganic CO prodrugsPharmacokinetics

Identifiers

PMID32745568
PMCPMC7606817
OpenAlexW3046503817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.